Kane Biotech Inc V.KNE

Alternate Symbol(s): KNBIF

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc > New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

<< Previous

Bullboard Posts

Next >>

Comment by francoisl13on Mar 21, 2024 10:49am

57 Views

Post# 35944917

RE:RE:RE:RE:New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

Interesting point of view. For my part, I'd rather keep the lower licensee fees for years to come and do my best to make sure Revyve sales pick-ups and covers expenses until a 2nd product comes to the market (ie.: gel spray, dermaKB, etc...).
I think the decision to sell or not the animal health related IP will depend on where they stand in regards to Revyve market penetration and 2024-256 expected sales level versus expected R&D and operational expenses.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project